US Ethics Approval Received for the Main Phase of FDA510(k)
Filed with ASX · · 3 pages · English
Earlier from BlinkLab
- Response to ASX Price and Volume Query
- Successful Placement of A$7.66M to Underpin Growth Strategy
- BlinkLab Surpasses Key Milestone in Pivotal U.S. Trial
- Pause in Trading
- US Autism Diagnostic Study Commences with First Child Tested
Later from BlinkLab
- 2025 Annual Report & Appendix 4E
- Pilot Study Confirms High Diagnostic Accuracy & Readiness
- Appointment of Managing Director and Board Changes
- High-Profile Journal Publication Validates BB1 Technology
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow BlinkLab into a list and get an email when it puts out news.
Follow BlinkLab